A Director at Genomic Health is Exercising Options


Yesterday it was reported that a Director at Genomic Health (NASDAQ: GHDX), Fred E. Cohen, exercised options to sell 8,250 GHDX shares at $25.79 a share, for a total transaction value of $463.8K.

Following Fred E. Cohen’s last GHDX Sell transaction on August 31, 2012, the stock climbed by 20.6%. This is Cohen’s first transaction since reporting a Sell transaction on BCRX back in September 2017

See today’s analyst top recommended stocks >>

Based on Genomic Health’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $95.62 million and quarterly net profit of $8.32 million. In comparison, last year the company earned revenue of $85.49 million and had a GAAP net loss of $2.74 million. GHDX’s market cap is $1.97B and the company has a P/E ratio of 500.73. Currently, Genomic Health has an average volume of 275.5K.

Six different firms, including Barclays and Merrill Lynch, currently also have a Sell rating on the stock. Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $51.08, reflecting a 7.8% upside.

In the last 30 days, insiders have sold $463.8K worth of GHDX shares and purchased $457.7K worth of GHDX shares. The insider sentiment on Genomic Health has been positive according to 53 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts